CoChat

A Pilot Double‐Blind Treatment Trial of Memantine for Alcohol Dependence

Evans, Suzette M., Levin, Frances R., Brooks, Daniel J., Garawi, Fatima · 2007 · Alcoholism: Clinical and Experimental Research
Cited by 101

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Background: There is growing evidence that N‐methyl‐d‐aspartate (NMDA) receptor antagonists may have potential for the treatment of alcohol disorders. Memantine is a selective noncompetitive NMDA receptor antagonist that has been shown to decrease alcohol craving in moderate drinkers. This 16‐week double‐blind outpatient pilot clinical trial determined if memantine was more effective than placebo at reducing alcohol use in actively drinking alcohol‐dependent patients. Methods: Forty‐four treatment‐seeking alcohol‐dependent individuals were enrolled, with 34 patients stratified to either the memantine group (n=19; maximum dose of 40 mg/d) or the placebo (PBO; n=15) group. The primary outcome measures were related to alcohol use (average drinks per day, average drinks per drinking day, percentage of heavy drinking days, and percentage of days abstinent) based on the timeline follow‐back (TLFB). Secondary outcome measures included the Obsessive Compulsive Drinking Scale, Clinical Global Impression ratings, and γ‐glutamyltransferase (GGT), a biomarker of recent alcohol use. To enhance retention, patients received voucher incentives for clinic attendance. Results: Of those randomized, approximately 80% (27) completed the entire 16‐week trial. Longitudinal analysis of drinks per day and drinks per drinking day showed a significant reduction in alcohol use, but no difference between the 2 groups. Further, the percentage of heavy drinking days indicated that both groups showed a significant decrease in drinking behavior, but there was significant treatment effect in favor of the PBO group. Similarly, for the percentage of days abstinent, the PBO group achieved a significantly greater percentage of days abstinent at a faster rate than the memantine group. Lastly, the memantine group reported a greater number of side effects compared with the PBO group, such that 26% of patients had their drug dose decreased or discontinued due to memantine‐related side effects. Conclusions: The results of this double‐blind placebo‐controlled pilot trial do not support the use of memantine for the treatment of actively drinking alcohol‐dependent patients. However, voucher incentives did facilitate retention.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1530-0277.2007.00360.x

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 101

Metadata

Authors
Evans, S. M., Levin, F. R., Brooks, D. J., & Garawi, F.
Venue
Alcoholism: Clinical and Experimental Research
Publisher
Wiley
Published
2007-03-22
Volume
31
Issue
5
Pages
775-782
ISSN
  • 0145-6008 (ISSN-L)
  • 1530-0277
OpenAlex
W1995943882
Cited by
101
References
6
FWCI
6.28
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Pilot Double‐Blind Treatment Trial of Memantine for Alcohol Dependence. https://app.cochat.ai/papers/10.1111/j.1530-0277.2007.00360.x
The paper
Evans, S. M., Levin, F. R., Brooks, D. J., & Garawi, F. (2007). A Pilot Double‐Blind Treatment Trial of Memantine for Alcohol Dependence. Alcoholism: Clinical and Experimental Research. https://doi.org/10.1111/j.1530-0277.2007.00360.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.